Phase 1 N=27 MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)
Alzheimer's Disease
Primary: Number of Participants With ≥1 Adverse Event (AE) — 13; 4; 4; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=57 Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment
Hepatic Impairment
Primary: AUC0-tau, Steady State — 96100; 107000; 103000; 69500 h•ng/mL
Phase 1 N=18 A Study to Learn About The Study Medicine (Called PF-06823859) in Healthy Chinese Participants
Healthy
Primary: Maximum Serum Concentration(Cmax) for PF-06823859 — 307.4 micrograms/milliliter (ug/mL)
Phase 1 N=28 A Study in Healthy Men to Test How BI 765080 is Taken up in the Body When Given as an Injection Under the Skin Compared With an Infusion Into the Vein
Healthy
Primary: Area Under the Concentration-time Curve of BI 765080 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 3528304.5; 7625263.8…
Phase 1 N=68 Pharmacokinetic Evaluation of Intranasal Nalmefene
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 12.2; 1.77 ng/ml
Phase 1 N=28 Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet
Healthy
Primary: Cmax — 4.880; 4.680; 3.860 (μg/mL)
Phase 1 N=34 Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Number of Participants With Treatment-emergent Adverse Events (All Causalities) — 5; 7; 6; 0 Participants
Phase 1 N=16 Potential for Cortisol Suppression With the Use of High Volume Nasal Mometasone Irrigations in Varying Dosages.
Chronic Rhinosinusitis (Diagnosis)
Primary: Morning "AM" Serum Cortisol Level — 17.35; 14.48 mcg/dL
Phase 1 N=141 Pharmacokinetic Comparability Study in Healthy Participants - PF-06881894 On-Body Injector Relative to Prefilled Syringe
Healthy Volunteers
Primary: Maximum Serum Concentration (Cmax) of PF-06881894 — 131.2; 161.1 nanogram per milliliter (ng/mL)
Phase 1 N=18 Study of Sulphoraphane in Chronic Kidney Disease
Chronic Kidney Disease stage3 · Chronic Kidney Disease stage4
Primary: Area Under the Concentration-Time Curve (AUC 0-8h) in Plasma — 700.0; 718.4 nmol h/L — p=0.931
Phase 1 N=99 Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Adverse Events of Special Interest (AESIs) From Study Vaccination Through the End of the Study — 1; 3; 2; 0 Participants
Phase 1 N=18 Tepotinib Hepatic Impairment Trial
Hepatic Impairment
Primary: Area Under the Plasma Concentration Time Curve From Time Zero to Infinity ( AUC0-inf ) of Tepotinib — 27500; 26100; 24200 Nanogram*hour per milliliter (ng*h/mL)
Phase 1 N=9 AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer
Advanced Non-small Cell Lung Cancer
Primary: Frequency and Causality of Serious Adverse Events (SAEs), Non-Serious Adverse Events (NSAEs) and Grade ≥3 Adverse Events (AEs) to AST-VAC2 — 0; 97; 3; 0 Adverse Events
Phase 1 N=20 A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese
Overweight · Obesity
Primary: Pharmacokinetics Parameter - Area Under the Concentration-Time Curve to Infinity (AUCinf) of PF-07081532 — 179400; 178300 nanogram*hour/milliliter (ng*hr/mL)
Phase 1 N=42 Effects of E-cigarette Flavors on Youth TCORS 2.0
Nicotine Use Disorder
Primary: Liking: Difference Score in Liking/Wanting of Each E-cigarette Condition — 1.268; -3.916 score on a scale — p=0.053